primer icon

John E. Gerich, MD
Professor Emeritus
Director of the Clinical Research Center
University of Rochester School of Medicine
Rochester, New York
 

Begin

CME/CE Information

Activity Title Metabolic Response to Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetic Patients
Topic Diabetes
Accreditation Type AMA PRA Category 1 Credit
Release Date May 2014
Expiration Date May 30, 2015 – No longer available for credit
Estimated Time to Complete Activity 15 minutes

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

  • Explain the rationale for targeting renal glucose transport, and interpret related clinical data and the potential role of SGLT2 inhibition in individualized T2DM therapies

FACULTY

John E. Gerich, MD
Professor Emeritus
Director of the Clinical Research Center
University of Rochester School of Medicine
Rochester, New York


METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant has 5 attempts to successfully pass.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  6. Your CME/CE certificate will be available for download

TECHNICAL REQUIREMENTS

This site is best viewed using Internet Explorer 8.0 or higher, or Firefox 4.0 or higher. For interactive content, a broadband connection is required. For all CME/CE activities featuring audio you must have a sound card and speakers.

Our interactive activities may require the Adobe Flash Player (available from the Adobe Web site) and Adobe Shockwave Player (available from the Adobe Web site). Both browser plug-ins are free.

Our activities may require JavaScript to be enabled on your computer.


ACCREDITED PROVIDER

This activity is provided by The France Foundation.


TARGET AUDIENCE

Primary care physicians and other health care professionals who manage patients with diabetes.


STATEMENT OF NEED

This activity is designed to improve knowledge, competency, and practice improvements in the diagnosis, management, and treatment of patients with type 2 diabetes mellitus (T2DM).


ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


RESOLUTION OF CONFLICTS OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, The France Foundation will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.


DISCLOSURES

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.


Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.


Faculty Disclosure

The following faculty has indicated he has relationships with industry to disclose relative to the content of this CME activity:

  • John E. Gerich, MD, has served as a consultant for Janssen, Boehringer Ingelheim, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Sanofi and has received honoraria from Janssen, Boehringer Ingelheim, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Sanofi, and Merck

UNAPPROVED USE DISCLOSURE

The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from AstraZeneca.


DISCLAIMER

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and AstraZeneca assume no liability for the information herein.


COPYRIGHT INFORMATION

Copyright © 2014 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.


CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or This email address is being protected from spambots. You need JavaScript enabled to view it..

 

Begin

 

 

The France Foundation

T2diabetescme.org is sponsored by The France Foundation.

Access other Therapeutic Areas: